Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria
Open Access
- 1 September 2021
- journal article
- research article
- Published by Elsevier BV in Kidney International
- Vol. 101 (3), 626-634
- https://doi.org/10.1016/j.kint.2021.08.015
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Hereditary causes of kidney stones and chronic kidney diseasePediatric Nephrology, 2013
- Primary Hyperoxaluria Type III Gene HOGA1 (Formerly DHDPSL) as a Possible Risk Factor for Idiopathic Calcium Oxalate UrolithiasisClinical Journal of the American Society of Nephrology, 2011
- Primary HyperoxaluriaInternational Journal of Nephrology, 2011
- Mutations in DHDPSL Are Responsible For Primary Hyperoxaluria Type IIIAmerican Journal of Human Genetics, 2010
- Genotype–phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcomeKidney International, 2010
- New Equations to Estimate GFR in Children with CKDJournal of the American Society of Nephrology, 2009
- Hydroxyproline ingestion and urinary oxalate and glycolate excretionKidney International, 2006
- The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type IIHuman Molecular Genetics, 1999
- Inhibition of oxalate synthesis: In vitro studies using analogues of oxalate and glycolateBiochemical Medicine, 1972
- Hyperoxaluria in L-Glyceric Aciduria: Possible Pathogenic MechanismScience, 1971